Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Bio-Synthesis Inc. currently manages a company patent portfolio with 1 pending office action in the Biotechnology & Pharmaceuticals technology area. This 1 action is assigned to 1 distinct art unit, reflecting a focused technical scope for the current prosecution. The involvement of 1 distinct examiner, GALSTER, SAMUEL LEONARD, means the outcome of the current portfolio activity depends on a single individual's interpretation of biotechnology standards.
Because GALSTER, SAMUEL LEONARD is the busiest examiner with 1 pending office action, there is no broader examiner pool to analyze within this specific data set. The 1 to 1 ratio between pending office actions and distinct examiners simplifies the management of the portfolio but increases the impact of this specific examiner's prior art search. Practitioners should focus on the specific requirements of the 1 art unit involved to successfully navigate this isolated prosecution event. This concentration of resources suggests that the applicant is prioritizing a specific pharmaceutical or biological innovation.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| GALSTER, SAMUEL LEONARD | 1 | 50.9% | +43.2% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19275384 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | GALSTER, SAMUEL LEONARD | 10d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19275384 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | GALSTER, SAMUEL LEONARD | 10d overdue |
| Art Unit | Apps |
|---|---|
| 1693 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19275384 | VERSATILE SYNTHETIC ROUTE FOR NEUTRAL MORPHOLINO OLIGONUCLEOTIDES WITH PHOSPHORYL GUANIDINIUM (PG) BACKBONE | GALSTER, SAMUEL LEONARD | 1693 | §103§112 | Final Rejection | 10d overdue | Pending | Jul 21, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial